| Gareth R Weiner, MD | |
|
10001 N Washington St, Thornton, CO 80229-2050 | |
| (303) 252-4442 | |
| (303) 429-6714 |
| Full Name | Gareth R Weiner |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 36 Years |
| Location | 10001 N Washington St, Thornton, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003845249 | NPI | - | NPPES |
| 01296839 | Medicaid | CO | |
| 100009339 | Other | CO | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 29683 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Platte Valley Medical Center | Brighton, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rocky Mountain Gastroenterology Associates, Pllc | 5991797532 | 48 |
News Archive
The world's third rectal microbicide trial launched in Pittsburgh, Pennsylvania today, with sites preparing to open in Boston, Massachusetts, and Birmingham, Alabama soon. Scientists will test the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.
Researchers from Nottingham's two universities are joining forces to develop a simple blood test to diagnose Alzheimer's disease.
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust.
A study made with 191 patients reveal that symptoms of hyperactivity due to the deficit of attention and hyperactivity disorder (ADHD) are associated with more impulsivity and more severity, and probably a worse prognosis in patients with eating disorders.
› Verified 7 days ago
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
The world's third rectal microbicide trial launched in Pittsburgh, Pennsylvania today, with sites preparing to open in Boston, Massachusetts, and Birmingham, Alabama soon. Scientists will test the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.
Researchers from Nottingham's two universities are joining forces to develop a simple blood test to diagnose Alzheimer's disease.
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust.
A study made with 191 patients reveal that symptoms of hyperactivity due to the deficit of attention and hyperactivity disorder (ADHD) are associated with more impulsivity and more severity, and probably a worse prognosis in patients with eating disorders.
› Verified 7 days ago
| Entity Name | Rocky Mountain Gastroenterology Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669414272 PECOS PAC ID: 5991797532 Enrollment ID: O20040401001433 |
News Archive
The world's third rectal microbicide trial launched in Pittsburgh, Pennsylvania today, with sites preparing to open in Boston, Massachusetts, and Birmingham, Alabama soon. Scientists will test the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.
Researchers from Nottingham's two universities are joining forces to develop a simple blood test to diagnose Alzheimer's disease.
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust.
A study made with 191 patients reveal that symptoms of hyperactivity due to the deficit of attention and hyperactivity disorder (ADHD) are associated with more impulsivity and more severity, and probably a worse prognosis in patients with eating disorders.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gareth R Weiner, MD 3333s Wadsworth Blvd D100, Lakewood, CO 80227-5117 Ph: (303) 205-1090 | Gareth R Weiner, MD 10001 N Washington St, Thornton, CO 80229-2050 Ph: (303) 252-4442 |
News Archive
The world's third rectal microbicide trial launched in Pittsburgh, Pennsylvania today, with sites preparing to open in Boston, Massachusetts, and Birmingham, Alabama soon. Scientists will test the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.
Researchers from Nottingham's two universities are joining forces to develop a simple blood test to diagnose Alzheimer's disease.
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust.
A study made with 191 patients reveal that symptoms of hyperactivity due to the deficit of attention and hyperactivity disorder (ADHD) are associated with more impulsivity and more severity, and probably a worse prognosis in patients with eating disorders.
› Verified 7 days ago
James C. Higham-kessler, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 10001 N. Washington Street, Upper Level, Thornton, CO 80229 Phone: 303-252-4442 | |
Matthew M Mcdiarmid, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 805 E 144th Ave Ste 100, Thornton, CO 80023 Phone: 720-772-8040 Fax: 720-805-1551 | |
Dr. Ashley Louise Pyle, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9195 Grant St Ste 110, Thornton, CO 80229 Phone: 720-536-2460 Fax: 720-536-2466 | |
Dr. Thomas A Haffey, D.O. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9141 Grant St, Suite 140, Thornton, CO 80229 Phone: 303-252-0104 Fax: 303-252-0127 | |
Katherine Blair Schuetze, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9195 Grant St Ste 200, Thornton, CO 80229 Phone: 303-252-0104 Fax: 303-252-8552 | |
Dr. Kevin P O'brien, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3260 E 104th Ave, Thornton, CO 80233 Phone: 720-929-8300 Fax: 720-929-8444 |